| Biomarker ID | 279 |
| PMID | 18500259 |
| Year | 2008 |
| Biomarker | Fusion Status of TMPRSS2:ERG + PTEN deletion |
| Biomarker Basis | Expression Based (Fusion Based) |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Fusion + Deletion |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.87 (95% CI: 1.04-3.36) |
| Effect on Pathways | Pathways include (PTEN): Immune system, Disease, T cell receptor regulation of apoptosis, Adaptive immune system, TGF-beta regulation of extracellular matrix |
| Experiment | Biochemical Recurrence Vs no Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 125 patients with radical prostatectomies were taken into consideration. 122 samples were selected for study of Biochemical recurrence. 62 did not had Biochemical recurrence and 60 did. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.036 |
| Method Used | Fluorescence In Situ Hybridization (FISH) |
| Clinical | No |
| Remarks | The endpoint for calculating the survival time was defined by time from radical prostatectomy until the occurrence of metastasis or PSA determined biochemical recurrence, ie the date of first PSA increase above 0.2 ng/ ml. (Multivariate Analysis for HR) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TMPRSS2, ERG, PTEN |